AVROBIO, Inc. (AVRO)

Market Cap	53.16M
Revenue (ttm)	n/a
Net Income (ttm)	12.16M
Shares Out	44.86M
EPS (ttm)	0.27
PE Ratio	4.39
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	94,733
Open	1.200
Previous Close	1.190
Day's Range	1.170 - 1.200
52-Week Range	0.570 - 1.700
Beta	1.24
Analysts	Hold
Price Target	2.00 (+68.78%)
Earnings Date	May 9, 2024

About AVRO

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trial...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 13
• Stock Exchange: NASDAQ
• Ticker Symbol: AVRO

Analyst Forecast

According to 3 analysts, the average rating for AVRO stock is "Hold." The 12-month stock price forecast is $2.0, which is an increase of 68.78% from the latest price.

Price Target

$2.0

(68.78% upside)

Analyst Consensus: Hold